• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pulm Pharmacol Ther . Evaluation of the Prophylactic Effect of Hydroxychloroquine on People in Close-Contact with Patients with Covid-19

tetano

Editor, Senior Moderator
Pulm Pharmacol Ther


. 2021 Aug 10;102069.
doi: 10.1016/j.pupt.2021.102069. Online ahead of print.
Evaluation of the Prophylactic Effect of Hydroxychloroquine on People in Close-Contact with Patients with Covid-19


Minoosh Shabani[SUP] 1 [/SUP], Mehdi Totonchi[SUP] 2 [/SUP], Omidvar Rezaeimirghaed[SUP] 3 [/SUP], Latif Gachkar[SUP] 1 [/SUP], Mohammadreza Hajiesmaeili[SUP] 4 [/SUP], Ali Khoshkar[SUP] 5 [/SUP], Mahdi Amirdosara[SUP] 4 [/SUP], Ali Saffaei[SUP] 6 [/SUP], Shervin Shokouhi[SUP] 1 [/SUP], Masoud Mardani[SUP] 1 [/SUP], Ilad Alavi Darazam[SUP] 1 [/SUP], Alireza Karami[SUP] 7 [/SUP], Milad Sharifi[SUP] 7 [/SUP], Mana Zaman[SUP] 8 [/SUP], Elham Abedheydari[SUP] 9 [/SUP], Zahra Sahraei[SUP] 10 [/SUP]



Affiliations

Abstract

Introduction: The coronavirus disease 2019 (COVID-19) pandemic has caused significant mortality worldwide. The disease attacks the lung tissue and may lead to acute respiratory distress syndrome. An in vitro study showed that hydroxychloroquine (HCQ) has a prophylactic effect against COVID-19 due to its anti-inflammatory effects. The present study aimed to evaluate the prophylactic effect of HCQ on individuals in close contact with patients with COVID-19.
Method: In this quasi-trial study, we prescribed HCQ for 7 days to all people who had close contact with a patient with COVID-19. All contacts underwent a nasal swab in two steps, and those positive for COVID-19 were excluded from the study. After 14 days of follow-up, the clinical and laboratory manifestations of COVID-19 were evaluated.
Results: A total of 113 participants completed the study. The HCQ group comprised 51 (45.13 %) contacts, and 62 (54.86 %) contacts were allocated to the control group. According to the results of clinical examination and real-time polymerase chain reaction test, 8 (12.90%) contacts in the control group were reported to have contracted COVID-19. In the HCQ group, 7 (13.72%) contacts were confirmed to have contracted COVID-19. There was no relationship between HCQ use and age, sex, underlying disorders, and laboratory data (all p >0.05). In terms of HCQ side effects, five participants experienced gastrointestinal and cutaneous side effects that subsided on discontinuation of HCQ.
Conclusion: The current study showed that HCQ had no prophylactic effect with regard to COVID-19 prevention.

Keywords: COVID-19; close contact; coronavirus; hydroxychloroquine.
 
Back
Top Bottom